These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35380586)

  • 41. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
    Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
    Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Security profile of direct anticoagulants. Preferred use in atrial fibrillation.
    Roldán Rabadán I; Alonso de Leciñana M; Barba Martín R; Páramo Fernández JA;
    Clin Investig Arterioscler; 2019; 31(6):263-270. PubMed ID: 31213323
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
    Sjögren V; Byström B; Renlund H; Svensson PJ; Oldgren J; Norrving B; Själander A
    PLoS One; 2017; 12(7):e0181000. PubMed ID: 28700711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
    Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
    Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
    Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients With Coronary Artery Disease and/or Peripheral Artery Disease.
    Lopes RD; Thomas L; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Friend K; Mardekian J; Pan X; Yuce H; Jones WS
    Am J Cardiol; 2021 Jun; 148():69-77. PubMed ID: 33667438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apixaban for the prevention of stroke in atrial fibrillation.
    Littrell R; Flaker G
    Expert Rev Cardiovasc Ther; 2012 Feb; 10(2):143-9. PubMed ID: 22292869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Atrial Fibrillation].
    Darius H
    Dtsch Med Wochenschr; 2020 Jul; 145(14):978-986. PubMed ID: 32668469
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.
    Miller CS; Grandi SM; Shimony A; Filion KB; Eisenberg MJ
    Am J Cardiol; 2012 Aug; 110(3):453-60. PubMed ID: 22537354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Real-World Direct Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Medicare Beneficiaries With Atrial Fibrillation.
    Yang L; Brooks MM; Glynn NW; Zhang Y; Saba S; Hernandez I
    Am J Cardiol; 2020 Jul; 126():29-36. PubMed ID: 32359718
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.
    Mendoza-Sanchez J; Silva F; Rangel L; Jaramillo L; Mendoza L; Garzon J; Quiroga A
    PLoS One; 2018; 13(5):e0196361. PubMed ID: 29723207
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 59. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation.
    Själander S; Sjögren V; Renlund H; Norrving B; Själander A
    Thromb Res; 2018 Jul; 167():113-118. PubMed ID: 29803981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.